Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SASHA COURTNEY DAVIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1194019075
CMS profile
2378874
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$209.43

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $209.43 5

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $96.24 1
Novocure Inc. $60.43 1
Karyopharm Therapeutics Inc. $18.81 1
E.R. Squibb & Sons, L.L.C. $17.62 1
AbbVie Inc. $16.33 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SASHA COURTNEY DAVIS

NPI 1194019075 · CMS profile ID 2378874

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $209.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $16.3311/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722144487 CMS
Novocure Inc. $60.4309/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740699187 CMS
E.R. Squibb & Sons, L.L.C. $17.6208/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727787363 CMS
Karyopharm Therapeutics Inc. $18.8108/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751735349 CMS
Celgene Corporation $96.2402/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727787383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $388.85 10
PY2020 $209.43 5
PY2021 $358.15 15
PY2022 $556.52 18
PY2023 $1,071.10 29
PY2024 $1,344.13 48
PY2025 $747.53 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $91,150.24 16
PY2024 Principal investigator $102,318.97 23
PY2023 Principal investigator $167,396.92 32
PY2022 Principal investigator $244,503.39 39
PY2021 Principal investigator $409,588.59 46
PY2020 Principal investigator $357,909.58 144
PY2019 Principal investigator $105,582.24 109

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $1,487.15 12/31/2023 Non-covered Recipient Entity
Texas Oncology-Tyler
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2 Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 1042504373
Principal investigator 1 Merck Sharp & Dohme LLC $7,769.65 12/31/2023 Non-covered Recipient Entity
Texas Oncology-Tyler
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2 Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 1042504383
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 10/30/2023 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1040058725
Principal investigator 1 Stemline Therapeutics Inc. $9,500.00 10/30/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1040059295
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,650.00 10/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 991130245
Principal investigator 1 Novartis Pharmaceuticals Corporation $48.60 10/09/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY - LONGVIEW CANCER CENTER
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy No dispute reported 06/30/2026 1017224553
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,507.99 10/09/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER PHARMACY
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy No dispute reported 06/30/2026 1017227011
Principal investigator 1 Novartis Pharmaceuticals Corporation $48.60 10/09/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PALESTINE CANCER CENTER
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy No dispute reported 06/30/2026 1017243247
Principal investigator 1 Genentech, Inc. $2,576.00 09/07/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040579283
Principal investigator 1 Genentech, Inc. $1,938.00 08/17/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040578461
Principal investigator 1 Genentech, Inc. $6,651.00 08/17/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040579067
Principal investigator 1 Genentech, Inc. $1,145.00 08/17/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040579201
Principal investigator 1 Stemline Therapeutics Inc. $9,500.00 07/27/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1040059255
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,063.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER PHARMACY
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy No dispute reported 06/30/2026 1017227155
Principal investigator 1 Veru Inc. $975.00 07/13/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
VERU001_V2000701_80052317 No dispute reported 06/30/2026 1058357419
Principal investigator 1 Veru Inc. $10,029.04 06/16/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
VERU001_V2000701_80052317 No dispute reported 06/30/2026 1058356801
Principal investigator 1 Genentech, Inc. $41,500.00 06/06/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040579421
Principal investigator 1 Genentech, Inc. $1,500.00 06/05/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040578677
Principal investigator 1 Genentech, Inc. $470.00 06/05/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040579885
Principal investigator 1 Genentech, Inc. $724.00 06/05/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040580051
Principal investigator 1 Stemline Therapeutics Inc. $9,500.00 06/01/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1040059031
Principal investigator 1 Stemline Therapeutics Inc. $9,500.00 04/24/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1040059083
Principal investigator 1 Eli Lilly and Company $0.04 04/19/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
POSTMONARCH: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+ HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 1038155037
Principal investigator 1 Eli Lilly and Company $3,186.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
POSTMONARCH: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+ HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 1038155029
Principal investigator 1 Novartis Pharmaceuticals Corporation $850.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER PHARMACY
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation No dispute reported 06/30/2026 1017222665
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,816.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER PHARMACY
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy No dispute reported 06/30/2026 1017222825
Principal investigator 1 Genentech, Inc. $6,600.00 03/23/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer No dispute reported 06/30/2026 1040578509
Principal investigator 1 Stemline Therapeutics Inc. $9,500.00 01/30/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1040059165
Principal investigator 1 PFIZER INC. $500.00 01/21/2023 Non-covered Recipient Entity
US Oncology LLC
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 1046534513
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,380.60 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 991124809
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,591.25 01/10/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER PHARMACY
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy No dispute reported 06/30/2026 1017206869
Principal investigator 1 Novartis Pharmaceuticals Corporation $890.00 01/01/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER PHARMACY
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation No dispute reported 06/30/2026 1017208087